Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

The Special Issue "In Vitro and In Vivo Models of Colorectal Cancer for Clinical Application", edited by Marta Baiocchi and Ann Zeuner for Cancers, collects original research papers and reviews, depicting the current state and the perspectives of CRC models for preclinical and translational research. Original research papers published in this issue focus on some of the hottest topics in CRC research, such as circulating tumor cells, epigenetic regulation of stemness states, new therapeutic targets, molecular CRC classification and experimental CRC models such as organoids and PDXs. Additionally, four reviews on CRC stem cells, immunotherapy and drug discovery provide an updated viewpoint on key topics linking benchtop to bedside research in CRC.

colorectal cancer --- organoids --- 3D bioprinting --- patient-derived xenograft --- cancer-on-chip --- drug combination --- cancer stem cells --- drug resistance --- clinical trials --- tumor-initiating cells --- tumor heterogeneity --- patient-derived cancer models --- single-cell RNA-sequencing --- tumor metabolism --- transcriptional programs --- tumor cell differentiation --- immunotherapy --- methods --- chromosomal instability --- DNA damage --- targeted therapy --- decitabine --- colon cancer --- DNA methylation --- clinical translation study --- machine learning --- patient-derived tumor organoid --- precision medicine --- radiation response --- rectal cancer --- PDX model --- CRC --- mutation analysis --- histological examination --- animal models --- in vitro culture --- cancer stem cell methods --- SATB2 --- colorectal carcinoma --- prognosis --- CDX2 --- circulating tumor cells --- CTC cluster --- size-based method --- ScreenCell® --- epithelial mesenchymal transition --- hypoxia --- HIF-1α --- immunofluorescence analysis --- sequential filtration

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

This book will cover topics related to the preparation and use of heterogeneous catalytic systems for the transformation of renewable sources, as well as of materials deriving from agro-industrial wastes and by-products. At the same time, the ever-increasing importance of bioproducts, due to the acceptance and request of consumers, makes the upgrade of biomass into chemicals and materials not only an environmental issue, but also an economical advantage.

isoselenourea --- malignant --- chemotherapeutics --- epigenetics --- antitumor activity --- methylseleninic acid --- mTOR inhibitors --- tumor heterogeneity --- hypoxia --- ER stress --- melanoma --- EMT --- lipid peroxidation --- immune evasion --- hypoxia-inducible factors (HIFs) --- selenium-binding protein 1 --- glutathione --- DNA damage --- hSP56 --- apoptosis --- tocopherol --- anticancer --- viability --- SELENBP1 --- selenium --- clear-cell renal cell carcinoma microRNAs --- SBP1 --- entosis --- PD-L1 --- miRNA --- cancer stem cells --- cell plasticity --- disease --- clear cell renal cell carcinoma --- HIF --- head and neck cancer --- selenium species --- VEGF --- STAT3 --- hypoxia-inducible factor --- methylselenocysteine --- anticancer agent --- Se-containing nanoparticles --- DNA damage and repair --- radiation --- seleno-l-methionine --- cancer --- tumor microenvironment --- methylselenoesters

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

The Special Issue "In Vitro and In Vivo Models of Colorectal Cancer for Clinical Application", edited by Marta Baiocchi and Ann Zeuner for Cancers, collects original research papers and reviews, depicting the current state and the perspectives of CRC models for preclinical and translational research. Original research papers published in this issue focus on some of the hottest topics in CRC research, such as circulating tumor cells, epigenetic regulation of stemness states, new therapeutic targets, molecular CRC classification and experimental CRC models such as organoids and PDXs. Additionally, four reviews on CRC stem cells, immunotherapy and drug discovery provide an updated viewpoint on key topics linking benchtop to bedside research in CRC.

Research & information: general --- Biology, life sciences --- Microbiology (non-medical) --- colorectal cancer --- organoids --- 3D bioprinting --- patient-derived xenograft --- cancer-on-chip --- drug combination --- cancer stem cells --- drug resistance --- clinical trials --- tumor-initiating cells --- tumor heterogeneity --- patient-derived cancer models --- single-cell RNA-sequencing --- tumor metabolism --- transcriptional programs --- tumor cell differentiation --- immunotherapy --- methods --- chromosomal instability --- DNA damage --- targeted therapy --- decitabine --- colon cancer --- DNA methylation --- clinical translation study --- machine learning --- patient-derived tumor organoid --- precision medicine --- radiation response --- rectal cancer --- PDX model --- CRC --- mutation analysis --- histological examination --- animal models --- in vitro culture --- cancer stem cell methods --- SATB2 --- colorectal carcinoma --- prognosis --- CDX2 --- circulating tumor cells --- CTC cluster --- size-based method --- ScreenCell® --- epithelial mesenchymal transition --- hypoxia --- HIF-1α --- immunofluorescence analysis --- sequential filtration --- colorectal cancer --- organoids --- 3D bioprinting --- patient-derived xenograft --- cancer-on-chip --- drug combination --- cancer stem cells --- drug resistance --- clinical trials --- tumor-initiating cells --- tumor heterogeneity --- patient-derived cancer models --- single-cell RNA-sequencing --- tumor metabolism --- transcriptional programs --- tumor cell differentiation --- immunotherapy --- methods --- chromosomal instability --- DNA damage --- targeted therapy --- decitabine --- colon cancer --- DNA methylation --- clinical translation study --- machine learning --- patient-derived tumor organoid --- precision medicine --- radiation response --- rectal cancer --- PDX model --- CRC --- mutation analysis --- histological examination --- animal models --- in vitro culture --- cancer stem cell methods --- SATB2 --- colorectal carcinoma --- prognosis --- CDX2 --- circulating tumor cells --- CTC cluster --- size-based method --- ScreenCell® --- epithelial mesenchymal transition --- hypoxia --- HIF-1α --- immunofluorescence analysis --- sequential filtration

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

The search for bioactive secondary metabolites from marine organisms has been an active area of research since the 1950s. The distinct biodiversity of the marine environment has afforded a vast array of unique secondary metabolites, many of which possess potent biological activities. This Special Issue of Marine Drugs will highlight recent bioactive marine natural product studies conducted by southern hemisphere scientists on an array of marine organisms.

Medicine --- Sinularia --- Alcyoniidae --- anticancer activity --- lobane --- cembrane --- diterpene --- conotoxins --- ShK toxin --- ion channels --- docking --- molecular dynamics --- potential of mean force --- free energy perturbation --- bioactivity --- biosynthesis --- brominated secondary metabolites --- choline ester --- indole --- sea cucumber --- viscera --- saponins --- mass spectrometry --- MALDI --- ESI --- HPCPC --- triterpene glycosides --- structure elucidation --- bioactive compounds --- marine invertebrate --- Echinodermata --- holothurian --- Cnemidocarpa stolonifera --- taurine amide --- PC3 cell line --- immunofluorescence assay --- thiaplidiaquinone --- Aplidium --- ascidian --- thiazinoquinone --- apoptosis --- Jurkat --- cytotoxicity --- malaria --- farnesyltransferase --- synthesis --- thiaplakortone --- regioisomer --- tricyclic --- natural product scaffold --- X-ray --- crystal --- Plasmodium falciparum --- antiplasmodial --- cephalostatin --- mandelalide --- methicillin resistant Staphylococcus aureus --- MRSA PK --- bisindole alkaloids --- salternamide A (SA) --- HIF-1α --- PI3K/Akt/mTOR --- p42/p44 MAPK --- STAT3 --- cell death --- Sinularia --- Alcyoniidae --- anticancer activity --- lobane --- cembrane --- diterpene --- conotoxins --- ShK toxin --- ion channels --- docking --- molecular dynamics --- potential of mean force --- free energy perturbation --- bioactivity --- biosynthesis --- brominated secondary metabolites --- choline ester --- indole --- sea cucumber --- viscera --- saponins --- mass spectrometry --- MALDI --- ESI --- HPCPC --- triterpene glycosides --- structure elucidation --- bioactive compounds --- marine invertebrate --- Echinodermata --- holothurian --- Cnemidocarpa stolonifera --- taurine amide --- PC3 cell line --- immunofluorescence assay --- thiaplidiaquinone --- Aplidium --- ascidian --- thiazinoquinone --- apoptosis --- Jurkat --- cytotoxicity --- malaria --- farnesyltransferase --- synthesis --- thiaplakortone --- regioisomer --- tricyclic --- natural product scaffold --- X-ray --- crystal --- Plasmodium falciparum --- antiplasmodial --- cephalostatin --- mandelalide --- methicillin resistant Staphylococcus aureus --- MRSA PK --- bisindole alkaloids --- salternamide A (SA) --- HIF-1α --- PI3K/Akt/mTOR --- p42/p44 MAPK --- STAT3 --- cell death

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

MicroRNAs (miRs) are small noncoding RNAs that function as post-transcriptional regulators of gene expression and have important roles in almost all biological pathways. Deregulated miR expression has been detected in numerous cancers, where miRs act as both oncogene and tumor suppressors. Due to their important roles in tumorigenesis, miRs have been investigated as prognostic and diagnostic biomarkers and as useful targets for therapeutic intervention. From a therapeutic point of view, two modalities can serve to rectify gene networks in cancer cells. For oncomiRs, a rational means is downregulation through antagomirs. Moreover, observations of the pathological reductions in tumor-suppressive miRs have inspired the concept of “miR replacement therapy” to enhance the amount of these miRs, thereby restoring them to normal levels. However, the clinical applicability of miR-based therapies is severely limited by the lack of effective delivery systems. Therefore, to understand the role of this new class of regulators, we need to identify the mRNA targets regulated by individual miRs as well as to develop specific, efficient, and safe delivery systems for therapeutic miRs.

Research & information: general --- Biology, life sciences --- Breast cancer --- Hypoxia inducible factor 1-alpha (HIF-1α) --- MicroRNA (miRNA) --- miR526b --- miR655 --- Oxidative stress --- Migration --- Cyclooxygenase-2 (COX-2) --- Prostaglandin E2 receptor 4 (EP4) --- PI3K/Akt --- adipokines --- endometrial cancer --- estrogens --- hyperinsulinemia --- insulin --- insulin resistance --- insulin signaling --- insulin-like growth factors --- microRNA --- miRNA --- ovarian cancer --- survival --- prognostic factor --- serum LDH --- blood biomarker --- circulating microRNA --- plasma --- immunotherapy --- immune checkpoint inhibitors --- metastatic melanoma --- hepatocellular carcinoma --- metastasis --- exosome --- bioinformatics analysis --- renal cancer --- RCC --- ccRCC --- meta-analysis --- miRNAs --- normal B-cell development --- B-CLL --- miRNA-transcription factor network --- regulation --- biomarker --- therapy --- prognosis --- diagnosis --- progression --- prediction --- smoking --- non-small cell lung cancer --- methylation --- miR-584-5p --- YKT6 --- snoRNA --- 2′-O-methylation --- pseudouridylation --- malignant melanoma --- cancer stem cell --- stemness --- head and neck squamous cell carcinoma --- colon cancer --- cancer stem cells --- microRNAs --- deformability --- PARP --- replication stress --- targeted therapy --- breast cancer --- circulating biomarkers --- medulloblastoma --- brain tumour --- subgroups --- stem cells --- n/a --- 2'-O-methylation